Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Semin Nephrol. 2022 Jan;42(1):63–75. doi: 10.1016/j.semnephrol.2022.01.003

Table 3.

Cancer-directed agents and transplant-specific concerns

Cancer-directed therapy Complications
Gemcitabine, anti-VEGF therapy* Thrombotic microangiopathy
IMiDs Acute rejection
Immune checkpoint inhibitors Acute interstitial nephritis, acute rejection and allograft loss
CAR-T therapy Infectious complications, acute rejection
*

agents known to be associated with thrombotic microangiopathy

Abbreviations: VEGF, vascular endothelial growth factor; IMiD, Immunomodulatory drugs; CAR-T, chimeric antigen receptor T cell